From: THE MEDICAL NEWS
Limerick BioPharma, Inc., a developer of innovative therapies that
help cells pump out unwanted or toxic substances, will announce new
results from human trials of its lead compound, LIM-0705, at the
23rd International Congress of the Transplantation Society in
Vancouver, Canada, in an oral presentation on August 19, 2010.
Respond to this topic on your own blog
Click and press Ctrl+C to copy and paste this discussion on your blog or site
Related Articles
ISC-SHRM and BCBSIL announce new workplace wellness program
The Illinois State Council of the Society for Human Resource
Management (ISC-SHRM) and Blue Cross and Blue Shield of Illinois
(BCBSIL) today announced a new awards program that recognizes
employers who champion the health of their employees and strive to
create a work culture that promotes physical activity.
Healthland's EMR solution product enhancements to be showcased at 2010 HIMSS Conference
Healthland, America's market leader of healthcare information
solutions for small community and critical access hospitals, today
announced it will exhibit at the 2010 Annual HIMSS Conference and
Exhibit, March 1- 4, 2010, in Atlanta at the Georgia World Congress
Center. At the event, Healthland will conduct product
demonstrations including its new Emergency Department Information
System and Healthland Analytics, report results from a recent
customer survey about the American Recovery and Reinvestment Act
(ARRA) and meaningful use, and announce recent client success
stories.
Study finds potential role of NGF in islet transplantation
Islet transplantation is a promising treatment for type 1 diabetes
mellitus. The promotion of angiogenesis is an important endeavor to
prevent islet graft failure. Endothelial precursor cells (EPCs), a
heterogeneous group originating in the hematopoietic compartment of
bone marrow, have an important role in the angiogenesis of adult
tissues.
New therapies increase survival rates in post-transplant liver cancer patients
A recent study found that sirolimus-based immunosuppression
following liver transplantation in patients with non-resectable
hepatocellular carcinoma (liver cancer) significantly increases
survival rates for this patient population. Results of this study
appear in the April issue of Hepatology, a journal published by
Wiley-Blackwell on behalf of the American Association for the Study
of Liver Diseases (AASLD).
Biologists discover new way to limit formation of teratomas
One of the characteristics of embryonic stem cells is their ability
to form unusual tumors called teratomas. These tumors, which
contain a mixture of cells from a variety of tissues and organs of
the body, are typically benign. But they present a major obstacle
to the development of human embryonic stem cell therapies that seek
to treat a variety of human ailments such as Parkinson's, diabetes,
genetic blood disorders and spinal cord injuries.